Cramer Gives His Opinion On Virgin Galactic, Zynex And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said Virgin Galactic Holdings Inc (NYSE: SPCE) is a very expensive stock. It had a nice run, but he would look for other stocks.
Citigroup Initiates Coverage On Haemonetics with Buy Rating, Announces Price Target of $75
Citigroup analyst Joanne Wuensch initiates coverage on Haemonetics (NYSE: HAE) with a Buy rating and announces Price Target of $75.Citigroup analyst Joanne Wuensch initiates coverage on Haemonetics (NYSE:HAE) with a Buy rating and announces Price Target of
CJS Securities Upgrades Haemonetics to Outperform
CJS Securities analyst Lawrence Solow upgrades Haemonetics (NYSE:HAE) from Market Perform to Outperform.
Jefferies Maintains Buy on Haemonetics, Lowers Price Target to $85
Jefferies analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Buy and lowers the price target from $105 to $85.
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 13)
77 Biggest Movers From Yesterday
Gainers
AMC Entertainment Holdings, Inc. (NYSE: AMC) shares surged 23.7% to close at $12.77.
Moxian, Inc. (NASDAQ: MOXC) jumped 23.6% to close at $9.52.
Earnings Scheduled For May 13, 2021
Companies Reporting Before The Bell
• CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 11)
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came under pressure following the U.S.